Last Updated : December 13, 2024
Details
FilesGeneric Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Advanced or recurrent endometrial carcinoma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0383-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
Pembrolizumab (Keytruda) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma (EC), and then continued as monotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | October 04, 2024 |
|---|---|
| Call for patient/clinician input closed | December 02, 2024 |
| Submission received | November 14, 2024 |
| Submission accepted | November 28, 2024 |
| Review initiated | November 29, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | February 21, 2025 |
| Deadline for sponsors comments | March 04, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | March 28, 2025 |
| Expert committee meeting (initial) | April 09, 2025 |
| Draft recommendation issued to sponsor | April 23, 2025 To April 25, 2025 |
| Draft recommendation posted for stakeholder feedback | May 01, 2025 |
| End of feedback period | May 15, 2025 |
Files
Last Updated : December 13, 2024